Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town.
S Afr Med J. 2010 Dec 1;100(12):827-31. doi: 10.7196/samj.4045.
To examine the uptake of ART among pregnant women referred to an ART service and the associated rates and risk factors for vertical HIV transmission.
Retrospective analysis of an observational cohort at a community ART clinic in Cape Town.
Between 2002 and 2008, 367 treatment-naive pregnant women accessed the clinic. The median age was 27.5 years, and median gestation at presentation was 28 weeks. The median baseline CD4 count and viral load were 134 cells/µl and 28 282 copies/ml. Two hundred and sixty-five women (72%) commenced ART before giving birth, 73 women (20%) were referred for prevention of mother-to-child transmission therapy (PMTCT), and 29 (8%) received no intervention. Among ART-eligible women, 13% were lost to follow-up. Of those starting ART, median duration of therapy prior to birth was 7.6 weeks (interquartile range (IQR) 4 - 11.9).The HIV transmission rate was 5.1% (95% confidence interval (CI) 2.8 - 9.0%). Factors associated with transmission were advanced maternal WHO disease stage (odds ratio (OR) 9.57, p=0.02), and follow-up viral load above 50 copies/ml (OR 3.64, p=0.03). Each additional week on ART reduced transmission by 20% (p=0.05). There was no HIV transmission among women who received more than 8 weeks' therapy.
The rate of HIV transmission in this study was higher than reported in high-income countries. Prevention of vertical transmission with ART was hindered by women presenting late in pregnancy and with advanced stage of HIV disease. Interventions that facilitate earlier ART commencement and improve programmatic retention of pregnant women are required.
调查转介至抗逆转录病毒治疗(ART)服务的孕妇接受抗逆转录病毒治疗的情况,以及垂直传播 HIV 的相关发生率和风险因素。
对开普敦社区抗逆转录病毒治疗诊所的观察性队列进行回顾性分析。
2002 年至 2008 年期间,有 367 名初次接受治疗的孕妇进入该诊所。中位年龄为 27.5 岁,就诊时的中位妊娠周数为 28 周。中位基线 CD4 计数和病毒载量分别为 134 个/µl 和 28282 拷贝/ml。265 名女性(72%)在分娩前开始接受抗逆转录病毒治疗,73 名女性(20%)被转介接受母婴传播预防治疗(PMTCT),29 名女性(8%)未接受任何干预。在符合抗逆转录病毒治疗条件的女性中,有 13%失访。开始接受抗逆转录病毒治疗的女性中,分娩前开始治疗的中位持续时间为 7.6 周(四分位间距 4-11.9)。HIV 传播率为 5.1%(95%置信区间(CI)为 2.8-9.0%)。与传播相关的因素是孕产妇的 WHO 疾病晚期(优势比(OR)为 9.57,p=0.02)和病毒载量高于 50 拷贝/ml(OR 为 3.64,p=0.03)。每增加一周的抗逆转录病毒治疗可使传播风险降低 20%(p=0.05)。接受超过 8 周治疗的女性中没有 HIV 传播。
本研究中的 HIV 传播率高于高收入国家的报告。抗逆转录病毒治疗预防垂直传播受到孕妇在妊娠晚期和 HIV 疾病晚期就诊的阻碍。需要采取干预措施,促进孕妇更早开始接受抗逆转录病毒治疗,并提高该方案对孕妇的保留率。